Investing IdeasBrowse All StocksMarkets
Have your own idea? Try our Stock Screener
Header cover image

Chinese (SSE) Clinical Research and Equipment Industry Analysis

UpdatedJul 07, 2026
DataAggregated Company Financials
Companies27
  • 7D0.4%
  • 3M12.7%
  • 1Y44.3%
  • YTDn/a

The Clinical Research and Equipment industry is up 7.3% in the last week, with Beijing Hotgen Biotech up 59%. This takes the industry's 12 month performance to a gain of 42%. Earnings are forecast to grow by 19% annually.

Industry Valuation and Performance

Has the Chinese Clinical Research and Equipment Industry valuation changed over the past few years?

DateMarket CapRevenueEarningsPEAbsolute PEPS
Tue, 07 Jul 2026CN¥661.8bCN¥98.8bCN¥21.9b61.1x30.3x6.7x
Thu, 04 Jun 2026CN¥542.8bCN¥98.8bCN¥21.9b49.9x24.8x5.5x
Sat, 02 May 2026CN¥617.3bCN¥98.4bCN¥21.7b58.6x28.5x6.3x
Mon, 30 Mar 2026CN¥559.6bCN¥94.1bCN¥20.2b57.9x27.7x5.9x
Wed, 25 Feb 2026CN¥598.6bCN¥94.4bCN¥18.6b68x32.3x6.3x
Fri, 23 Jan 2026CN¥606.3bCN¥94.3bCN¥18.5b64.6x32.7x6.4x
Sun, 21 Dec 2025CN¥557.5bCN¥94.3bCN¥18.5b61.9x30.1x5.9x
Tue, 18 Nov 2025CN¥567.2bCN¥94.3bCN¥18.5b68.3x30.6x6x
Thu, 16 Oct 2025CN¥584.8bCN¥92.1bCN¥17.4b64.1x33.5x6.3x
Sat, 13 Sep 2025CN¥625.2bCN¥92.1bCN¥17.4b72.1x35.8x6.8x
Mon, 11 Aug 2025CN¥562.9bCN¥91.6bCN¥17.9b57.2x31.5x6.1x
Wed, 09 Jul 2025CN¥458.5bCN¥89.8bCN¥15.4b51.4x29.8x5.1x
Fri, 06 Jun 2025CN¥426.8bCN¥89.8bCN¥15.4b49.2x27.7x4.8x
Sun, 04 May 2025CN¥390.9bCN¥89.5bCN¥15.1b40x25.8x4.4x
Tue, 01 Apr 2025CN¥432.6bCN¥88.5bCN¥14.0b42.6x30.9x4.9x
Thu, 27 Feb 2025CN¥437.5bCN¥88.1bCN¥11.3b45.6x38.8x5x
Sat, 25 Jan 2025CN¥361.6bCN¥88.1bCN¥11.2b38.1x32.2x4.1x
Mon, 23 Dec 2024CN¥382.5bCN¥87.8bCN¥11.2b39.7x34.2x4.4x
Wed, 20 Nov 2024CN¥371.0bCN¥87.8bCN¥11.2b39.3x33.2x4.2x
Fri, 18 Oct 2024CN¥341.1bCN¥88.2bCN¥12.4b31.2x27.6x3.9x
Sun, 15 Sep 2024CN¥279.8bCN¥88.2bCN¥12.4b27.5x22.6x3.2x
Tue, 13 Aug 2024CN¥292.3bCN¥87.6bCN¥12.6b27x23.3x3.3x
Thu, 11 Jul 2024CN¥267.8bCN¥88.3bCN¥13.4b23.2x20x3x
Sat, 08 Jun 2024CN¥303.0bCN¥88.3bCN¥13.4b26.8x22.6x3.4x
Mon, 06 May 2024CN¥327.0bCN¥89.0bCN¥13.5b30.1x24.2x3.7x
Wed, 03 Apr 2024CN¥339.8bCN¥90.3bCN¥15.0b33.8x22.6x3.8x
Fri, 01 Mar 2024CN¥363.2bCN¥90.5bCN¥15.5b32.1x23.4x4x
Sun, 28 Jan 2024CN¥404.4bCN¥91.1bCN¥16.1b33.7x25.1x4.4x
Tue, 26 Dec 2023CN¥472.1bCN¥91.1bCN¥16.1b36.2x29.4x5.2x
Thu, 23 Nov 2023CN¥538.4bCN¥91.1bCN¥16.1b37.5x33.5x5.9x
Sat, 21 Oct 2023CN¥511.7bCN¥92.2bCN¥18.4b33.4x27.8x5.5x
Mon, 18 Sep 2023CN¥488.8bCN¥92.0bCN¥18.3b32.5x26.7x5.3x
Wed, 16 Aug 2023CN¥495.9bCN¥91.6bCN¥18.6b34.8x26.7x5.4x
Fri, 14 Jul 2023CN¥468.2bCN¥91.3bCN¥18.5b35.2x25.3x5.1x
Price to Earnings Ratio

25.3x


Total Market Cap: CN¥468.2bTotal Earnings: CN¥18.5bTotal Revenue: CN¥91.3bTotal Market Cap vs Earnings and Revenue0%0%0%
Chinese Clinical Research and Equipment Industry Price to Earnings3Y Average 28.7x202420252026
Current Industry PE
  • Investors are relatively neutral on the Chinese Life Sciences Tools and Services industry at the moment, indicating that they anticipate long term growth rates to remain steady.
  • The industry is trading close to its 3-year average PE ratio of 28.7x.
  • The 3-year average PS ratio of 5.0x is lower than the industry's current PS ratio of 6.7x.
Past Earnings Growth
  • The earnings for companies in the Life Sciences Tools and Services industry have grown 5.8% per year over the last three years.
  • Revenues for these companies have grown 2.7% per year.
  • This means that more sales are being generated by these companies overall, and subsequently their profits are increasing too.

Industry Comparison

How does Chinese Clinical Research and Equipment compare with similar industries?

CN Market-1.13%
Healthcare5.44%
Life Sciences0.44%
Clinical Research and Equipment0.44%
Industry PEThere are no additional sub-industries under this industry.
Forecasted GrowthThere are no additional sub-industries under this industry.

Top Stock Gainers and Losers

Which companies have driven the market over the last 7 days?

CompanyLast Price7D1YValuation
688068 Beijing Hotgen BiotechCN¥130.0050.1%
+CN¥3.8b		-25.1%PS26.7x
300759 Pharmaron BeijingCN¥30.575.7%
+CN¥3.0b		23.0%PE33x
688114 MGI TechCN¥54.095.9%
+CN¥1.2b		-12.9%PS7.7x
603127 Joinn Laboratories(China)Co.LtdCN¥39.232.6%
+CN¥740.7m		58.5%PE58.1x
301520 Anhui Wanbang Pharmaceutical TechnologyLtdCN¥37.7416.1%
+CN¥486.1m		20.5%PE143.9x

Latest News

688238
CN¥5.95
Shanghai Obio Technology (Group)
7D
9.8%
1Y
-11.6%
300347
CN¥46.30
Hangzhou Tigermed Consulting
7D
-3.5%
1Y
-17.9%
301257
CN¥48.31
SMO ClinPlusLTD
7D
6.5%
1Y
46.4%
301333
CN¥51.98
R&G PharmaStudies
7D
3.8%
1Y
2.0%
688758
CN¥21.02
Suzhou Sepax Technologies
7D
-4.5%
1Y
25.1%
301096
CN¥53.10
Hangzhou Bio-Sincerity Pharma-TechLtd
7D
-7.2%
1Y
18.8%
300759
CN¥30.57
Pharmaron Beijing
7D
5.7%
1Y
23.0%
301520
CN¥37.74
Anhui Wanbang Pharmaceutical TechnologyLtd
7D
16.1%
1Y
20.5%
603127
CN¥39.23
Joinn Laboratories(China)Co.Ltd
7D
2.6%
1Y
58.5%
688114
CN¥54.09
MGI Tech
7D
5.9%
1Y
-12.9%
688068
CN¥130.00
Beijing Hotgen Biotech
7D
50.1%
1Y
-25.1%
688131
CN¥87.05
Shanghai Haoyuan Chemexpress
7D
-8.0%
1Y
64.7%
688621
CN¥51.15
Beijing Sun-Novo Pharmaceutical Research
7D
-6.8%
1Y
5.2%
688202
CN¥75.61
Shanghai Medicilon
7D
-6.3%
1Y
66.9%
688046
CN¥23.04
GemPharmatech
7D
-4.8%
1Y
55.2%
603259
CN¥118.30
WuXi AppTec
7D
-5.0%
1Y
68.0%
Narrative Update • Jun 29

603259: APAC Conviction List Inclusion Will Support Upside From Ongoing Share Buybacks

Analysts have raised their fair value estimate for WuXi AppTec from CN¥137.83 to CN¥145.96, citing updated assumptions for revenue growth, profit margins, discount rate, and future P/E that are reflected in recent research, including its addition to a major APAC conviction list. What's in the News for WuXi AppTec WuXi AppTec's Board of Directors authorized a new share buyback plan on June 9, 2026, signaling continued use of repurchases as a capital management tool.